The Phase 2/3 approval and CTA submission are significant catalysts for this micro-cap biotech, but the company has only $2.4M cash and a $1M market cap. Monitor for additional financing needs and the actual trial initiation in Q2 2026. The stock is highly speculative with a history of large negative moves post-report.
Price Chart
Executive Summary
Silexion received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer and submitted a CTA to Germany. The trial is on track for Q2 2026. The company reported a Q1 2026 net loss of $2.7M on $0 revenue, with cash burn reducing cash to $2.4M, and subsequently raised ~$1.0M via a warrant exercise to address Nasdaq listing compliance.
Key Financial Metrics
Key Facts
- Israeli Ministry of Health approved Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.
- Clinical Trial Application submitted to Germany via EU CTIS; Germany is the Reporting Member State.
- Phase 2/3 trial initiation on track for Q2 2026 with ~18-patient safety run-in and ~166-patient randomized cohort.
- Q1 2026 net loss of $2.7M vs $1.7M in Q1 2025; cash and equivalents fell to $2.4M from $6.0M at year-end 2025.
- May 2026 warrant exercise generated ~$1.0M gross proceeds; company believes it has restored Nasdaq equity compliance.
Financial Impact
Q1 2026 net loss $2.7M; cash burn $3.6M in Q1; subsequent $1.0M warrant exercise; no revenue.
Risk Factors
- Cash runway is extremely limited (~$2.4M) with no revenue; likely needs additional dilutive financing.
- Phase 2/3 trial may fail to enroll or show efficacy; pancreatic cancer is a notoriously difficult indication.
- Nasdaq continued listing compliance remains fragile despite recent equity raise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296613 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers